Keratin 17 and A2ML1 are negative prognostic biomarkers in non-small cell lung cancer
Babu S, Horowitz M, Delgado-Coka L, Roa-Peña L, Akalin A, Escobar-Hoyos L, Shroyer K. Keratin 17 and A2ML1 are negative prognostic biomarkers in non-small cell lung cancer. Pathology - Research And Practice 2024, 263: 155643. PMID: 39413460, DOI: 10.1016/j.prp.2024.155643.Peer-Reviewed Original ResearchNon-small cell lung cancerLung squamous cell carcinomaNegative prognostic biomarkerCell lung cancerSquamous cell carcinomaPancreatic ductal adenocarcinomaPrognostic biomarkerCell carcinomaMultiplex immunohistochemistryPrognostic accuracyDuctal adenocarcinomaLung cancerPrimary lung squamous cell carcinomaHead and neck squamous cell carcinomaNeck squamous cell carcinomaImpact treatment decisionsClinicopathological factorsClinicopathological variablesOverall prognosisPulmonary adenocarcinomaSolid tumorsNon-smallSurvival differencesPrognostic dataCo-testingKeratin 17 modulates the immune topography of pancreatic cancer
Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton C, Hasan M, Babu S, Fassler D, Oentoro J, Bai J, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos L, Shroyer K. Keratin 17 modulates the immune topography of pancreatic cancer. Journal Of Translational Medicine 2024, 22: 443. PMID: 38730319, PMCID: PMC11087249, DOI: 10.1186/s12967-024-05252-1.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaCD8+ T cellsT cellsK17 expressionCell carcinomaPatient survivalMolecular subtypes of pancreatic ductal adenocarcinomaIntratumoral CD8+ T cellsSpatial distribution of T cellsKeratin 17CD8+ T cell abundanceImmune responseSubtype of pancreatic ductal adenocarcinomaCervical squamous cell carcinomaAssociated with decreased numbersCD16+ macrophagesTumor-intrinsic variablesDistribution of T cellsLymph node statusSquamous cell carcinomaBasal cell carcinomaCD163+ macrophagesT cell abundanceImmune cell responsesImmunotherapeutic opportunities